Steward Partners Investment Advisory’s Krystal Biotech KRYS Stock Holding History

Steward Partners Investment Advisory’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$25.8K	Buy	+100	New	+$26.6K	﹤0.01%	3111

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Steward Partners Investment Advisory's KRYS Position: Q1 2026 in Review

Steward Partners Investment Advisory opened a new position in Krystal Biotech (KRYS) in Q1 2026: 100 shares worth $25.8K. The stake represents ﹤0.01% of the portfolio and ranks #3111 among its holdings.

367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

Steward Partners Investment Advisory held 100 shares of Krystal Biotech worth $25.8K as of Q1 2026.
Krystal Biotech was a new Steward Partners Investment Advisory position in Q1 2026.
Krystal Biotech made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q1 2026, its #3111 holding.
367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q1 2026, filed 8 May 2026.